(R)-tert-butyl 2-isopropylpyrrolidine-1-carboxylate | 1218922-02-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-tert-butyl 2-isopropylpyrrolidine-1-carboxylate
• 英文别名: N-Boc-(R)-2-isopropylpyrrolidine；tert-Butyl (R)-2-isopropylpyrrolidine-1-carboxylate；tert-butyl (2R)-2-propan-2-ylpyrrolidine-1-carboxylate
• CAS: 1218922-02-1
• 化学式: C₁₂H₂₃NO₂
• 分子量: 213.32
• InChiKey: JIQIYRNJTWFMBB-SNVBAGLBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (R)-tert-butyl 2-isopropylpyrrolidine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 (R)-2-isopropylpyrrolidine
  参考文献：
  名称：

  外消旋烷基金属试剂与未活化仲烷基亲电子试剂的对映交叉偶联：N-Boc-吡咯烷的催化不对称 Negishi α-烷基化

  摘要：

  尽管已经开发了外消旋亲电子试剂的对映异构烷基-烷基偶联，但还没有外消旋亲核试剂的相应反应的报道。在此，我们描述了外消旋 α-锌化 N-Boc-吡咯烷与未活化的仲卤化物的根岸交叉偶联，从而为合成一系列 2-烷基吡咯烷（目标分子的重要家族）提供了一种一锅催化不对称方法。来自 N-Boc-吡咯烷，一种市售前体。初步机制研究表明，两种最直接的对映体聚合机制（有机金属偶联伙伴的动态动力学拆分和简单的 β-氢化物消除/β-迁移插入途径）不太可能起作用。

  DOI：

  10.1021/ja4054114
• 作为产物：
  描述：

  2-碘代丙烷 、 1-Boc-四氢吡咯 在 四甲基乙二胺 、 仲丁基锂 、 zinc(II) iodide 、 氯化镍二甲氧基乙烷 、 (1R,2R)-N1,N2-dimethyl-1,2-di(naphthalen-1-yl)ethane-1,2-diamine 作用下， 以 乙醚 、 环己烷 、 四氢呋喃 为溶剂， 反应 65.0h， 以83%的产率得到(R)-tert-butyl 2-isopropylpyrrolidine-1-carboxylate
  参考文献：
  名称：

  外消旋烷基金属试剂与未活化仲烷基亲电子试剂的对映交叉偶联：N-Boc-吡咯烷的催化不对称 Negishi α-烷基化

  摘要：

  尽管已经开发了外消旋亲电子试剂的对映异构烷基-烷基偶联，但还没有外消旋亲核试剂的相应反应的报道。在此，我们描述了外消旋 α-锌化 N-Boc-吡咯烷与未活化的仲卤化物的根岸交叉偶联，从而为合成一系列 2-烷基吡咯烷（目标分子的重要家族）提供了一种一锅催化不对称方法。来自 N-Boc-吡咯烷，一种市售前体。初步机制研究表明，两种最直接的对映体聚合机制（有机金属偶联伙伴的动态动力学拆分和简单的 β-氢化物消除/β-迁移插入途径）不太可能起作用。

  DOI：

  10.1021/ja4054114

文献信息

• CLASS- AND ISOFORM-SPECIFIC HDAC INHIBITORS AND USES THEREOF
  申请人：Mazitschek Ralph

  公开号：US20120208889A1

  公开（公告）日：2012-08-16

  HDAC inhibitors of the general formula (I) and (II) and pharmaceutically acceptable salts thereof, as described herein, are useful as inhibitors of histone deacetylases or other deacetylases, and thus are useful for the treatment of various diseases and disorders associated with acetylase/deacetylase activity as described herein (e.g., cancer). In certain embodiments, the compounds of the invention selectively target either a class or isoform of the HDAC family. Another aspect of the invention provides an assay for determining the inhibitory effect of a test compound on an HDAC protein comprising: incubating the HDAC protein with a substrate of general formula (IIIc) in the presence of a test compound; and determining the activity of the HDAC protein.

  本文描述的具有一般式（I）和（II）及其药学上可接受的盐的HDAC抑制剂，可用作组蛋白去乙酰化酶或其他去乙酰化酶的抑制剂，并因此可用于治疗与去乙酰化酶/乙酰化酶活性相关的各种疾病和疾病，如本文所述（例如癌症）。在某些实施例中，本发明的化合物有选择性地靶向HDAC家族的一类或同工酶。本发明的另一个方面提供了一种测定试验化合物对HDAC蛋白质抑制作用的测定方法，包括：在试验化合物的存在下，将HDAC蛋白质与一般式（IIIc）的底物孵育，并确定HDAC蛋白质的活性。
• Hepatitis C Virus Inhibitors
  申请人：Bristol-Myers Squibb Company

  公开号：US20130085147A1

  公开（公告）日：2013-04-04

  The present disclosure is generally directed to antiviral compounds, and more specifically directed to compounds which can inhibit the function of the NS5A protein encoded by Hepatitis C virus (HCV), compositions comprising such compounds, and methods for inhibiting the function of the NS5A protein.

  本公开涉及抗病毒化合物，更具体地涉及能够抑制丙型肝炎病毒（HCV）编码的NS5A蛋白质功能的化合物，包含这些化合物的组合物，以及抑制NS5A蛋白质功能的方法。
• INDOLE COMPOUNDS AS EZH2 INHIBITORS AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：EP3885343A1

  公开（公告）日：2021-09-29

  The present disclosure provides compounds of Formula (II). The compounds described herein are inhibitors of histone methyltransferases (e.g., enhancer of zeste homolog 1 (EZH1) and enhancer of zeste homolog 2 (EZH2)) and are useful in treating and/or preventing a broad range of diseases (e.g., proliferative diseases). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein. Further provided in the present disclosure are methods of identifying EZH1 and/or EZH2 inhibitors.

  本公开提供了式（II）化合物。 本文所述化合物是组蛋白甲基转移酶（如泽斯特同源增强子 1 (EZH1) 和泽斯特同源增强子 2 (EZH2)）的抑制剂，可用于治疗和/或预防多种疾病（如增殖性疾病）。本公开还提供了包括或使用本文所述化合物的药物组合物、试剂盒、方法和用途。本公开还提供了鉴定EZH1和/或EZH2抑制剂的方法。
• Bis(2-alkylpyrrolidin-1-yl)methylidenes as Chiral Acyclic Diaminocarbene Ligands
  作者：David R. Snead、Sebastien Inagaki、Khalil A. Abboud、Sukwon Hong

  DOI：10.1021/om901112n

  日期：2010.4.12

  2-Alkylpyrrolidines were used as building blocks for acyclic diaminocarbenes (ADCs). First, ureas were made from the corresponding amines, and then the urns were converted to chloro-amidiniums. The chloroamidiniums served as direct precursors to ADCs, and palladium complexes were made utilizing oxidative addition, whereas lithium halogen exchange was performed to generate rhodium complexes. The carbene ligands were characterized through use of NMR, mass spectrometry, and X-ray analysis, and from X-ray structures, steric parameters were calculated as % V-Bur values. The ability of these ligands to direct stereochemistry and enhance activity was explored in the Suzuki cross-coupling reaction and the 1,2 addition of arylboronic acids to aldehydes.
• DIAZEPANE DERIVATIVES AND USES THEREOF
  申请人：Dana-Farber Cancer Institute, Inc.

  公开号：US20170145023A1

  公开（公告）日：2017-05-25

  The present disclosure provides compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) have been found to bind bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (BET) proteins). Also provided are methods, uses, and kits of the compounds and pharmaceutical compositions for inhibiting the activity (e.g., increased activity) of bromodomains and/or bromodomain-containing proteins and for treating and/or preventing in a subject diseases associated with bromodomains or bromodomain-containing proteins (e.g., proliferative diseases, cardiovascular diseases, viral infections, fibrotic diseases, neurological diseases, metabolic diseases, endocrine diseases, and radiation poisoning). The compounds, pharmaceutical compositions, and kits are also useful for male contraception.